ClinicalTrials.gg

Program

HS235

A development code.

Its studies are mostly in Hypertension, Pulmonary · Pulmonary Arterial Hypertension · Obesity, led by 2 companies.

Furthest: phase 2, since Aug 8, 20253 company-led studies, 2 open or runningNext primary completion: Mar 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
35Pharma Inc., a GSK22 open or runningphase 2since Aug 8, 2025Aug 8, 2025Mar 2028phase 2 · NCT07143448
35Pharma10 open or runningphase 1since Nov 27, 2024Nov 27, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2024First study: phase 1 study in OverweightNew to 35Pharma35Pharma · NCT06714825 · 39 enrolled · Canada
  2. Aug 8, 202535Pharma Inc., a GSK's first studies: 2 phase 2 studiesNew to 35Pharma Inc., a GSK35Pharma Inc., a GSK · NCT07123779, NCT07143448

Ahead

  1. Mar 2028Primary completion: phase 2 study in Pulmonary Arterial Hypertension35Pharma Inc., a GSK · NCT07143448
  2. Jan 2029Primary completion: phase 2 study in Hypertension, Pulmonary35Pharma Inc., a GSK · NCT07123779

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07143448Pulmonary Arterial Hypertension · United States, Spain, United Kingdom2Recruiting35Pharma Inc., a GSKMar 202890
NCT07123779Hypertension, Pulmonary · United States2Recruiting35Pharma Inc., a GSKJan 2029126
NCT06714825Overweight · Canada1Completed35PharmaDec 2, 202539

How it is read

Names in the registry

  • “HS235”, 3 entries

Codes read as this program: HS235.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
HS235 (35Pharma Inc., a GSK): development program | ClinicalTrials.gg